Movatterモバイル変換


[0]ホーム

URL:


JPH0314002B2 - - Google Patents

Info

Publication number
JPH0314002B2
JPH0314002B2JP56095691AJP9569181AJPH0314002B2JP H0314002 B2JPH0314002 B2JP H0314002B2JP 56095691 AJP56095691 AJP 56095691AJP 9569181 AJP9569181 AJP 9569181AJP H0314002 B2JPH0314002 B2JP H0314002B2
Authority
JP
Japan
Prior art keywords
vitamin
lecithin
fat
vegetable oil
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP56095691A
Other languages
Japanese (ja)
Other versions
JPS57209216A (en
Inventor
Yoshiaki Kaneshiro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NIPPON SEIYAKU KK
Original Assignee
NIPPON SEIYAKU KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NIPPON SEIYAKU KKfiledCriticalNIPPON SEIYAKU KK
Priority to JP9569181ApriorityCriticalpatent/JPS57209216A/en
Publication of JPS57209216ApublicationCriticalpatent/JPS57209216A/en
Publication of JPH0314002B2publicationCriticalpatent/JPH0314002B2/ja
Grantedlegal-statusCriticalCurrent

Links

Landscapes

Description

Translated fromJapanese
【発明の詳細な説明】[Detailed description of the invention]

近年、経口的に栄養補給ができない患者に、
糖、電解質、アミノ酸、脂肪、ビタミン、ミネラ
ルなどを水溶液または水分散液の形で静脈より投
与する栄養輸液療法が急速に普及しつつある。同
様に栄養源の1種である脂溶性ビタミンをこの方
法で投与するには、例えば合成界面活性剤で水溶
化した製剤が用いられる。しかし、かかる製剤に
おいては合成界面活性剤使用に基づく副作用もと
きおり報告され、この種の製剤は栄養輸液療法に
とつて必ずしも適当とはいえない。また栄養補給
という点では油性注射液を用いることもできる
が、このときは筋肉内注射のため、投与経路が増
え、患者にとつて苦痛を増すことになる。 本発明者等は脂溶性ビタミンを水溶化するので
はなく、静注が可能な程度に微粒子状に乳化・分
散せしめ、かつ安定に保存し得るような注射剤を
製造すべく、種々検討を重ねてきた。その結果、
脂溶性ビタミン筋肉内注射剤の溶剤として汎用さ
れている植物油に溶解し、レシチンを乳化剤とし
て水に乳化することによつて前記の目的を満たす
静注可能な注射液を製造することに成功した。 本発明では使用する脂溶性ビタミン類にはビタ
ミンAまたはそのエステル、ビタミンD2または
D3、ビタミンEまたはそのエステル、およびビ
タミンK1またはK2があり、本発明はこれらのビ
タミン類から2種以上を使用する複合ビタミンで
ある。 植物油としては、大豆油、ゴマ油、綿実油など
注射剤の溶剤として用いられるものなら特に限定
されない。レシチンは、卵黄レシチン、大豆レシ
チンのいずれも用いることができる。 人に必要とされる脂溶性ビタミンの量は、これ
を限定することはできないが、製剤の配合される
量の一例としてビタミンA2500IU、ビタミン
D200IU、ビタミンE15mg、ビタミンK2mgをあげ
ることができる。本発明により上記量の脂溶性ビ
タミン類を溶解し、かつ水1mlに乳化させるに当
り、使用しうる植物油とレシチンの混合物の量は
0.01〜0.05g、好ましくは0.02〜0.03gであり、植
物油とレシチンの比は重量比で1:1〜4とす
る。この比率であれば乳化性は良好で、比較的小
さな機械的剪断力をもつてしても容易に1μ以下
の粒径とすることができる。また滅菌や保存に対
して安定とするには、、塩酸、硫酸、リン酸のよ
うな鉱酸あるいは酢酸、クエン酸、乳酸のような
有機酸または水酸化トリウムの希薄水溶液を使つ
てpHを4〜8に調整する。また滲透圧を血液と
等張とするため、ブドウ糖、果糖のような糖類、
ソルビツト、マンニツトのごとき多価アルコール
を添加するとよい。これらは乳化する水に溶解し
ておいてもよいし、乳化後に添加してもよい。 この乳化液を例えばアンプル中に溶封する場
合、酸化防止のためにアンプル空間を窒素のよう
な不活性ガスで置換する必要がある。かくして製
造した注射剤を静脈内に投与するには、直接その
ままでもよいし、各種の輸液に混合してもよい。 以下に実施例を挙げて本発明を説明する。実施
例中、温度は摂氏である。実施例 1 ビタミンAパルミテート40万単位、ビタミン
D24万単位、ビタミンEアセテート3g、ビタミン
K20.4g、大豆油2g、卵黄レシチン4gを窒素気流
中で約70゜の水浴中で加熱しながら均一に混合す
る。これに、5W/Vソルビツト水溶液(水酸化
ナトリウムでpH8に調整)180mlを70〜80゜に加熱
して加え、同温度に保ちながら、窒素気流中で
TKホモミキサー(特殊機化工業K.K)用いて
6000rpmで30分間乳化する。室温まで冷却した
後、蒸留水を加えて全量200mlとする。 ミリポアフイルターで過し、1ml褐色アンプ
ルに分注、空間を窒素で置換して溶閉し、100゜,
60分滅菌する。 かくして得られた乳化液は均一な乳濁液で、、
粒度をコールターカウンターで測定したとき、分
布極大径は0.3μ以下、顕微鏡による最大径は1μ以
下であつた。滅菌後の各ビタミンの残存率は、W
%で表わしてAパルミテート98.8%、D297.5%、
Eアセテート99.2%、K298.5%であつた。実施例 2 ビタミンAアルコール25万単位、ビタミンD31
万単位、ビタミンEアセテート1.5g、ビタミン
K10.15g、大豆油0.5g、卵黄レシチン1.5gを窒素
気流中で約70゜の水浴中で加熱、混合する。これ
に、ソルビツト5W/V%、アスコルビン酸
0.05W/V%を含み、水酸化ナトリウムでpH8に
調節された水溶液180mlを70〜80゜に加熱して加
え、同温度に保ちながら、窒素気流中でTKホモ
ミキサーを用いて6000rpmで20分間乳化する。室
温まで冷却し、蒸留水を加えて全量200mlとする。
ミリポアフイルターで過し、2ml褐色アンプル
に分注、空間を窒素で置換して溶閉し、100゜、60
分滅菌する。 乳化液の性状は実施例1と同じである。滅菌後
の残存率はW%で表わしてAアルコール98%、
D398.5%、Eアセテート99.5%、K199%であつ
た。実施例 3 実施例1で調製した乳化液200mlを、5W/V%
ソルビツト水溶液800mlに撹拌しながら添加し、
均一に混合稀釈する。ミリポアフイルターで過
して5ml褐色アンプルに分注、空間を窒素で置換
して溶閉し、100゜,60分滅菌する。 乳化液の粒度、各ビタミンの安定性は実施例1
で調製した注射液と同等である。実施例 4 ビタミンAパルミテート50万単位、ビタミン
D34万単位、ビタミンEアセテート2g、ビタミン
K10.3g、大豆油3g、大豆レシチン3gを窒素気流
中で加温、均一に混合する。これに70〜80゜に加
熱した5W/V%ブドウ糖水溶液180mlを加え、窒
素気流中、TKホモミキサーを用いて10000rpm
で20分間乳化する。 室温まで冷却して蒸留水を加え、全量200mlと
する。 ミリポアフイルターで過し、1ml褐色アンプ
ルに分注、空間を窒素で置換して溶閉し、100゜、
60分滅菌する。試験例 ビタミンAパルミテート20万単位、ビタミン
D22万単位、ビタミンEアセテート1.5g、ビタミ
ンK20.2g、大豆油1gに卵黄レシチンをそれぞれ
0.5g、0.75g、1g、4gまたは6g(それぞれ試験No.
1,2,3,4および5とする)を加えたものに
5W/V%ソルビツト水溶液90ml(水酸化ナトリ
ウムでpH8に調整した)を70〜80゜に加熱して加
え、同温度に保ちながら窒素気流中でTKホモミ
キサーを用いて6000rpmで30分間乳化する。室温
まで冷却した後、蒸溜水を加えて全量を100mlと
する。 これらをそれぞれミリポアフイルターで過
し、それぞれ1mlアンプルに分注し、空間を窒素
で置換して溶閉し、100゜、60分滅菌する。 これらを40℃で保存した。 滅菌製造直後および40゜で3ケ月保存後、粒子
径および外観を観察した。その結果を表1に示
す。
In recent years, patients who cannot receive nutritional support orally,
Nutrient infusion therapy, in which sugars, electrolytes, amino acids, fats, vitamins, minerals, etc. are intravenously administered in the form of an aqueous solution or dispersion, is rapidly becoming popular. Similarly, to administer fat-soluble vitamins, which are a type of nutritional source, using this method, for example, a preparation made water-soluble with a synthetic surfactant is used. However, side effects due to the use of synthetic surfactants are sometimes reported in such preparations, and such preparations are not necessarily suitable for nutritional infusion therapy. Oil-based injections can also be used for nutritional support, but in this case, intramuscular injection increases the number of administration routes and increases pain for the patient. The inventors of the present invention did not make fat-soluble vitamins water-soluble, but instead emulsified and dispersed them into fine particles to the extent that they could be injected intravenously, and conducted various studies in order to produce an injection that could be stably stored. It's here. the result,
By dissolving fat-soluble vitamins in vegetable oil, which is commonly used as a solvent for intramuscular injections, and emulsifying them in water using lecithin as an emulsifier, we succeeded in producing an intravenously injectable solution that satisfies the above objectives. The fat-soluble vitamins used in the present invention include vitamin A or its ester, vitaminD2 or
D3 , vitamin E or its ester, and vitaminK1 orK2 , and the present invention is a complex vitamin using two or more of these vitamins. The vegetable oil is not particularly limited as long as it can be used as a solvent for injections, such as soybean oil, sesame oil, and cottonseed oil. As lecithin, either egg yolk lecithin or soybean lecithin can be used. The amount of fat-soluble vitamins required by humans cannot be limited, but examples of the amount that can be added to a preparation include vitamin A2500IU, vitamin
I can give you 200 IU of D, 15 mg of vitamin E, and 2 mg of vitamin K. According to the present invention, when dissolving the above amount of fat-soluble vitamins and emulsifying it in 1 ml of water, the amount of the mixture of vegetable oil and lecithin that can be used is
The amount is 0.01 to 0.05 g, preferably 0.02 to 0.03 g, and the ratio of vegetable oil to lecithin is 1:1 to 4 by weight. With this ratio, the emulsifying property is good and the particle size can be easily reduced to 1 μm or less even with a relatively small mechanical shearing force. To make it stable for sterilization and storage, the pH should be adjusted to 4 using a mineral acid such as hydrochloric acid, sulfuric acid, or phosphoric acid, or an organic acid such as acetic acid, citric acid, or lactic acid, or a dilute aqueous solution of thorium hydroxide. Adjust to ~8. In addition, in order to make the osmotic pressure isotonic with the blood, sugars such as glucose and fructose,
It is recommended to add polyhydric alcohols such as sorbitol and mannitol. These may be dissolved in the water to be emulsified, or may be added after emulsification. When this emulsion is sealed in an ampoule, for example, it is necessary to replace the ampoule space with an inert gas such as nitrogen to prevent oxidation. In order to administer the injection prepared in this way intravenously, it may be administered directly as it is or may be mixed with various infusion solutions. The present invention will be explained below with reference to Examples. In the examples, temperatures are in degrees Celsius. Example 1 400,000 units of vitamin A palmitate, vitamin
D2 40,000 units, vitamin E acetate 3g, vitamin
Mix 0.4gof K2 , 2g of soybean oil, and 4g of egg yolk lecithin uniformly while heating in a water bath at about 70° in a nitrogen stream. To this, add 180ml of 5W/V sorbitol aqueous solution (adjusted to pH 8 with sodium hydroxide) heated to 70-80°, and while maintaining the same temperature, add it in a nitrogen stream.
Using TK homomixer (Tokushu Kika Kogyo KK)
Emulsify for 30 minutes at 6000 rpm. After cooling to room temperature, add distilled water to make a total volume of 200 ml. Filter through a Millipore filter, dispense into 1 ml brown ampoules, replace the space with nitrogen, close the solution, and heat to 100°.
Sterilize for 60 minutes. The emulsion thus obtained is a homogeneous emulsion.
When the particle size was measured using a Coulter counter, the maximum diameter of the distribution was 0.3μ or less, and the maximum diameter under a microscope was 1μ or less. The residual rate of each vitamin after sterilization is W
Expressed in %, A palmitate 98.8%, D2 97.5%,
E acetate was 99.2% and K2 was 98.5%. Example 2 Vitamin A alcohol 250,000 units, vitamin D3 1
10,000 units, vitamin E acetate 1.5g, vitamin
Heat and mix 0.15 g of K1 , 0.5 g of soybean oil, and 1.5 g of egg yolk lecithin in a water bath at about 70° in a nitrogen stream. To this, sorbitol 5W/V%, ascorbic acid
Add 180 ml of an aqueous solution containing 0.05 W/V% and adjusted to pH 8 with sodium hydroxide by heating to 70-80°, and while maintaining the same temperature, mix for 20 minutes at 6000 rpm in a nitrogen stream using a TK homomixer. Emulsify. Cool to room temperature and add distilled water to make a total volume of 200 ml.
Pass through a Millipore filter, dispense into 2 ml brown ampoules, replace the space with nitrogen and close the solution, 100°, 60°
Sterilize for minutes. The properties of the emulsion are the same as in Example 1. The residual rate after sterilization is 98% of A alcohol expressed in W%.
D3 was 98.5%, E acetate was 99.5%, and K1 was 99%. Example 3 200ml of the emulsion prepared in Example 1 was added to 5W/V%
Add to 800ml of sorbitol aqueous solution while stirring,
Mix and dilute evenly. Pass through a Millipore filter, dispense into 5 ml brown ampoules, replace the space with nitrogen, seal, and sterilize at 100° for 60 minutes. The particle size of the emulsion and the stability of each vitamin are as shown in Example 1.
It is equivalent to the injection solution prepared in . Example 4 500,000 units of vitamin A palmitate, vitamin
D3 40,000 units, vitamin E acetate 2g, vitamin
0.3gof K1 , 3g of soybean oil, and 3g of soybean lecithin are heated in a nitrogen stream and mixed uniformly. Add 180ml of 5W/V% glucose aqueous solution heated to 70-80°, and mix at 10,000 rpm using a TK homo mixer in a nitrogen stream.
Emulsify for 20 minutes. Cool to room temperature and add distilled water to make a total volume of 200 ml. Pass through a Millipore filter, dispense into 1 ml brown ampoules, replace the space with nitrogen, close the solution, and heat to 100°.
Sterilize for 60 minutes. Test example: 200,000 units of vitamin A palmitate, vitamin
D2 20,000 units, vitamin E acetate 1.5g, vitamin K2 0.2g, soybean oil 1g and egg yolk lecithin each
0.5g, 0.75g, 1g, 4g or 6g (Test No.
1, 2, 3, 4 and 5) plus
Add 90 ml of 5W/V% sorbitol aqueous solution (adjusted to pH 8 with sodium hydroxide) heated to 70-80°, and emulsify for 30 minutes at 6000 rpm using a TK homomixer in a nitrogen stream while maintaining the same temperature. After cooling to room temperature, add distilled water to make a total volume of 100 ml. Each of these is passed through a Millipore filter, dispensed into 1 ml ampoules, and the space is replaced with nitrogen, sealed, and sterilized at 100° for 60 minutes. These were stored at 40°C. Particle size and appearance were observed immediately after sterile production and after storage at 40° for 3 months. The results are shown in Table 1.

【表】 表1の結果から明らかなように、植物油対レシ
チンの重量比を本発明に従つて1:1〜4とする
ことにより、滅菌製造直後は勿論、40゜で3ケ月
保存後も外観および粒子共に良好であつた。これ
に対し、上記範囲外では特に40゜で3ケ月保存後
安定性が不良である。
[Table] As is clear from the results in Table 1, by adjusting the weight ratio of vegetable oil to lecithin to 1:1 to 4 according to the present invention, the appearance of the product can be maintained not only immediately after sterilized production but also after storage at 40° for 3 months. and particles were both good. On the other hand, outside the above range, the stability is poor especially after storage at 40° for 3 months.

Claims (1)

Translated fromJapanese
【特許請求の範囲】1 ビタミンAまたはそのエステル、ビタミン
D2またはD3、ビタミンEまたはそのエステル、
およびビタミンK1またはK2よりなる群より選択
した2種以上の脂溶性ビタミン、植物油、レシチ
ンを含有し、植物油対レシチンの重量比を1:1
〜4とした静脈注射可能な複合脂溶性ビタミン注
射液。2 ビタミンAまたはそのエステル、ビタミン
D2またはD3ビタミンEまたはそのエステル、お
よびビタミンK1またはK2よりなる群から選択し
た2種以上の脂溶性ビタミンを植物油に溶解し、
この溶液をレシチンの存在下に水に乳化し、上記
植物油対レシチンの重量比を1:1〜4とするこ
とを特徴とする安定な静脈内注射用複合脂溶性ビ
タミン注射液の製造法。
[Claims] 1. Vitamin A or its ester, vitamin
D2 or D3 , vitamin E or its ester,
and two or more fat-soluble vitamins selected from the group consisting of vitamin K1 or K2 , vegetable oil, and lecithin, and the weight ratio of vegetable oil to lecithin is 1:1.
An intravenously injectable complex fat-soluble vitamin injection with a rating of ~4. 2 Vitamin A or its ester, vitamin
Two or more fat-soluble vitamins selected from the group consisting of D2 orD3 vitamin E or its ester, and vitaminK1 orK2 are dissolved in vegetable oil,
A method for producing a stable intravenous complex fat-soluble vitamin injection comprising emulsifying this solution in water in the presence of lecithin so that the weight ratio of the vegetable oil to lecithin is 1:1 to 4.
JP9569181A1981-06-191981-06-19Compound fat-soluble vitamin injection capable of being medicated by venoclysis and its preparationGrantedJPS57209216A (en)

Priority Applications (1)

Application NumberPriority DateFiling DateTitle
JP9569181AJPS57209216A (en)1981-06-191981-06-19Compound fat-soluble vitamin injection capable of being medicated by venoclysis and its preparation

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
JP9569181AJPS57209216A (en)1981-06-191981-06-19Compound fat-soluble vitamin injection capable of being medicated by venoclysis and its preparation

Publications (2)

Publication NumberPublication Date
JPS57209216A JPS57209216A (en)1982-12-22
JPH0314002B2true JPH0314002B2 (en)1991-02-25

Family

ID=14144514

Family Applications (1)

Application NumberTitlePriority DateFiling Date
JP9569181AGrantedJPS57209216A (en)1981-06-191981-06-19Compound fat-soluble vitamin injection capable of being medicated by venoclysis and its preparation

Country Status (1)

CountryLink
JP (1)JPS57209216A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
JPS58162517A (en)*1982-03-191983-09-27Green Cross Corp:The Fat emulsion containing fat-soluble vitamins
JPH01113315A (en)*1987-10-231989-05-02Lederle Japan LtdFat emulsion containing vitamin k2

Citations (2)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3384545A (en)*1965-03-091968-05-21Hoffmann La RocheInjectable aqueous emulsions of fat soluble vitamins
JPS5356315A (en)*1976-11-011978-05-22Eisai Co LtdEmulsified solution of fat soluble drugs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3384545A (en)*1965-03-091968-05-21Hoffmann La RocheInjectable aqueous emulsions of fat soluble vitamins
JPS5356315A (en)*1976-11-011978-05-22Eisai Co LtdEmulsified solution of fat soluble drugs

Also Published As

Publication numberPublication date
JPS57209216A (en)1982-12-22

Similar Documents

PublicationPublication DateTitle
Collins-Gold et al.Parenteral emulsions for drug delivery
US6528067B1 (en)Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US5997904A (en)Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
AU710143B2 (en)Oil in water emulsions containing propofol and edetate
JP2003535884A (en) Improved injectable dispersion of propofol
JPH06510772A (en) Pharmaceutical carrier made of solid lipid microparticles (solid lipid nanospheres)
CA2199414A1 (en)Stable carotenoid emulsions suitable for parenteral administration
JPS6139924B2 (en)
JPH0510327B2 (en)
BRPI0506812B1 (en) anhydrous self-microemulsifiable base composition, microemulsion and method of preparing the self-emulsifiable base composition
JPS5924132B2 (en) Manufacturing method for nutritional supplement emulsion
KR20170071467A (en)Application of Large-Dose Glycerinum in Freeze-Thawing Tolerable Lipid Emulsion
JPS62270521A (en) Flurbiprofen ophthalmic preparation
JPH10510267A (en) Emulsion suitable for administration of sphingolipid and use thereof
KR100211772B1 (en) Lyophilized emulsions containing the active substance
JPH047724B2 (en)
JPS58162517A (en) Fat emulsion containing fat-soluble vitamins
JPH0314002B2 (en)
JPH08508016A (en) Pharmaceutical composition in kit form
JP3446035B2 (en) Infusion preparation
JPH059112A (en) Infusion formulation
JP2002179562A (en)Stable painless propofol fat emulsion for intravenous injection
EP0313617B1 (en)Lipid emulsion and method for intravenous infusion
CN102178651B (en)Tretinoin fat emulsion injection and preparation method thereof
JPH0422886B2 (en)

[8]ページ先頭

©2009-2025 Movatter.jp